AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2026)

AbCellera Biologics has reported Other Operating Expenses for 7 years, with the latest figure at $938000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 1.74% year-over-year to $938000.0; the trailing twelve-month figure through Mar 2026 stood at $993000.0 (down 98.66% YoY), and the FY2025 full-year result was $3.8 million, down 95.19% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $938000.0, up from -$7.8 million in the prior quarter.
• The five-year high for Other Operating Expenses was $49.6 million in Q1 2022, with the low at -$7.8 million in Q4 2025.
• Historically, Other Operating Expenses has averaged $11.1 million across 5 years, with a median of $6.1 million in 2023.
• Annual changes were most pronounced in 2024 — Other Operating Expenses soared 494.04% — and 2025, when it plunged 997.0%.
• AbCellera Biologics' Other Operating Expenses stood at $15.3 million in 2022, then tumbled by 148.75% to -$7.5 million in 2023, then surged by 111.61% to $867000.0 in 2024, then sank by 997.0% to -$7.8 million in 2025, then soared by 112.06% to $938000.0 in 2026.
• The last three Other Operating Expenses figures came in at $938000.0 (Q1 2026), -$7.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.